Professor Dr Evgeni Ponimaskin and Dr Josephine Labus stand in front of a laser microscope at the MHH Institute of Neurophysiology. Copyright: Karin Kaiser / MHH
Professor Dr Evgeni Ponimaskin and Dr Josephine Labus stand in front of a laser microscope at the MHH Institute of Neurophysiology. Copyright: Karin Kaiser / MHH A clinical trial will investigate the drug's efficacy in dementia patients. A common feature of many neurodegenerative diseases are pathological protein deposits in the brain. These protein aggregates cause nerve cells to die and, as a result, entire brain areas to shrink, which manifests itself in affected individuals as progressive dementia. The so-called tau protein in particular is involved in the development of neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. A research team led by Professor Dr Evgeni Ponimaskin, a scientist at the MHH Institute of Neurophysiology , has already discovered that signal transmission through a specific serotonin receptor called 5-HT7R plays a crucial role in this process. Now, in collaboration with international scientists, the MHH team has investigated the effect of the antipsychotic amisulpride on the receptor.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
